Title Big on promise, big on cost: Which patients warrant this cholesterol-busting wonder drug? Degree of recognition National Media name/outlet Australian Doctor Media type Web Country Australia Date 7/08/19 Description Meet the new lipid-lowering agents: monoclonal antibodies that promise to shrink LDL to levels lower than even the strongest statin could achieve.
PCSK9 inhibitors have captured attention for their potential to cut stroke and myocardial infarction risk, as well as for their substantial cost, an estimated $8000 per year.
This article discusses the funding and evaluation of expensive medications.
Producer/Author Emily Dunn, Australian Doctor Group Persons Mark Morgan